{{Rsnum
|rsid=8099917
|Chromosome=19
|position=39252525
|Orientation=plus
|GMAF=0.1382
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(G;G)
|geno2=(G;T)
|geno3=(T;T)
}}{{ population diversity
| geno1=(G;G)
| geno2=(G;T)
| geno3=(T;T)
| CEU | 2.7 | 24.8 | 72.6
| HCB | 0.0 | 12.4 | 87.6
| JPT | 0.9 | 20.4 | 78.8
| YRI | 0.7 | 3.4 | 95.9
| ASW | 0.0 | 19.3 | 80.7
| CHB | 0.0 | 12.4 | 87.6
| CHD | 0.9 | 11.0 | 88.1
| GIH | 2.0 | 32.7 | 65.3
| LWK | 0.0 | 11.8 | 88.2
| MEX | 8.6 | 46.6 | 44.8
| MKK | 1.3 | 20.0 | 78.7
| TSI | 1.0 | 40.2 | 58.8
| HapMapRevision=28
}}[http://blog.23andme.com/2009/09/18/snpwatch-more-evidence-that-genetic-variations-are-important-for-hepatitis-c-infection-and-treatment/ 23andMe blog] 

[[rs8099917]](C) less likely to respond to [[Hepatitis C]] treatment. 

[[rs12979860]](C;C) better able to become naturally [[Hepatitis C]] virus-free.
[[rs12980275]](A)  usually corresponds to the [[rs12979860]](C)
{{PMID Auto GWAS
|PMID=19749758
|Trait=Response to Hepatitis C treatment
|Title=IL28B is associated with response to chronic hepatitis C interferon-alpha and ribavirin therapy
|RiskAllele=G
|Pval=9E-9
|OR=1.98
|ORtxt=[1.57-2.52]
}}
{{PMID Auto GWAS
|PMID=19749757
|Trait=Response to Hepatitis C treatment
|Title=Genome-wide association of IL28B with response to pegylated interferon-alpha and ribavirin therapy for chronic hepatitis C
|RiskAllele=G
|Pval=3E-32
|OR=27.10
|ORtxt=[14.6-50.3]
}}

{{omim
|desc=INTERLEUKIN 28B; IL28B
|id=607402
|rsnum=8099917
}}

{{PMID Auto GWAS
|PMID=20060832
|Trait=Chronic Hepatitis C infection
|Title=Genetic variation in IL28B Is Associated with Chronic Hepatitis C and Treatment Failure - A Genome-Wide Association Study
|RiskAllele=G
|Pval=6E-9
|OR=2.31
|ORtxt=[1.74-3.06]
}}

{{PMID Auto
|PMID=20576307
|Title=A common variation of IL28 affects gamma-GTP levels and inflammation of the liver in chronically infected hepatitis C virus patients
}}
{{PMID Auto
|PMID=20803561
|Title=Potential role for interleukin-28B genotype in treatment decision-making in recent hepatitis C virus infection
|OA=1
}}

{{PharmGKB
|RSID=rs8099917
|Name_s=
|Gene_s=IL28B
|Feature=
|Evidence=PubMed ID:19749757
|Annotation=Risk or phenotype-associated allele: G. Phenotype: This variant is associated with null virological response (NVR) and sustained virologic response (SVR) in Janapese patients with hepatitis C virus infection treated with PEG-INF-alpha plus ribavirin. Study size: Initial sample:154; Replication Sample: 172. Study population/ethnicity: Japanese. Significance metric(s): P=3.11 x 10(-15) (NVR); P = 1.11 x 10(-27)(SVR). Type of association: GN; CO
|Drugs=interferon alfa-2a, recombinant; ribavirin
|Drug Classes=
|Diseases=Hepatitis C; Hepatitis C, Chronic
|Curation Level=Curated
|PharmGKB Accession ID=PA165260379
}}
{{PMID Auto
|PMID=21068134
|Title=HCV substitutions and IL28B polymorphisms on outcome of peg-interferon plus ribavirin combination therapy
}}

{{omim
|id=609532
|rsnum=8099917
}}

{{PMID Auto
|PMID=21382156
|Title=Genes and hepatitis C: susceptibility, fibrosis progression and response to treatment
}}

{{PMID Auto
|PMID=21384511
|Title=Relationship between the interleukin-28b gene polymorphism and the histological severity of hepatitis C virus-induced graft inflammation and the response to antiviral therapy after liver transplantation
}}

{{PMID Auto GWAS
|PMID=21228123
|Trait=None
|Title=IL-28B predicts response to chronic hepatitis C therapy -fine-mapping and replication study in Asian populations
|RiskAllele=G
|Pval=1E-20
|OR=3.0000
|ORtxt=[2.4-3.8]
}}

{{PMID Auto
|PMID=21618576
|Title=Impact of viral amino acid substitutions and host IL28B polymorphism on replication and susceptibility to interferon of hepatitis C virus
}}

{{PMID Auto
|PMID=21722179
|Title=Predicting response to therapy in chronic hepatitis C: an approach combining IL28B gene polymorphisms and clinical data
}}

{{PMID Auto
|PMID=21390311
|Title=Response prediction in chronic hepatitis C by assessment of IP-10 and IL28B-related single nucleotide polymorphisms
|OA=1
}}

{{PMID Auto
|PMID=21914076
|Title=IL28B polymorphism may guide pegylated interferon plus ribavirin therapy even after curative treatment for hepatitis C virus-related hepatocellular carcinoma
}}

{{PMID Auto
|PMID=21987611
|Title=IL28B polymorphisms associated with therapy response in Chilean chronic hepatitis C patients
|OA=1
}}

{{PMID Auto
|PMID=21994136
|Title=Ultra-Rapid Virological Response, Young Age, Low ?-GT/ALT-Ratio, and Absence of Steatosis Identify a Subgroup of HCV Genotype 3 Patients Who Achieve SVR with IFN-?(2a) Monotherapy
|OA=1
}}

{{PMID Auto
|PMID=22032680
|Title=Eradication of hepatitis C virus genotype 1 after liver transplantation by interferon therapy before surgery: Report of three patients with analysis of interleukin-28 polymorphism, hepatitis C virus core region and interferon-sensitivity determining region
}}

{{PMID Auto
|PMID=22052088
|Title=Interleukin-28B genotypes determine response to pegylated-interferon             plus ribavirin therapy in patients with hepatitis C virus infection
}}

{{PMID Auto
|PMID=22087138
|Title=Single nucleotide polymorphisms of the IL28B and sustained virologic response of patients with chronic hepatitis C to PEG-interferon/ribavirin therapy: A meta-analysis: Meta-analysis of IL28B
|OA=1
}}

{{PMID Auto
|PMID=22118055
|Title=Single and combined IL28B, ITPA and SLC28A3 host genetic markers modulating response to anti-hepatitis C therapy
}}

{{PMID Auto
|PMID=22174846
|Title=Hepatic STAT1-Nuclear Translocation and Interleukin 28B Polymorphisms Predict Treatment Outcomes in Hepatitis C Virus Genotype 1-Infected Patients
|OA=1
}}

{{PMID Auto
|PMID=22234924
|Title=Combined effects of different IL28B gene variants on the outcome of dual combination therapy in chronic HCV type 1 infection
}}

{{PMID Auto
|PMID=22257210
|Title=A Tetra-Primer Amplification Refractory Mutation System-Polymerase Chain Reaction for the Detection of rs8099917 IL28B Genotype
}}

{{PMID Auto
|PMID=22336553
|Title=[Studies on the relationship between polymorphism of IL-28B rs8099917 and the outcome of HBV infection]
}}

{{PMID Auto
|PMID=22336134
|Title=Paradoxical expression of IL-28B mRNA in peripheral blood in human T-cell leukemia virus Type-1 mono-infection and Co-infection with hepatitis C Virus
|OA=1
}}

{{PMID Auto
|PMID=22356575
|Title=The outcomes of glucose abnormalities in pre-diabetic chronic hepatitis C patients receiving peginterferon plus ribavirin therapy
}}

{{PMID Auto
|PMID=22374338
|Title=Evaluation of interleukin 28B single nucleotide polymorphisms in infants suffering from bronchiolitis
}}

{{PMID Auto
|PMID=21745312
|Title=Association of interleukin 28B and mutations in the core and NS5A region of hepatitis C virus with response to peg-interferon and ribavirin therapy
}}

{{PMID Auto
|PMID=22521237
|Title=Closed tube method for rapid screening of IL28B polymorphisms involved in response to hepatitis C treatment
}}

{{PMID Auto
|PMID=22550527
|Title=Development and Validation of a Simple, Rapid and Inexpensive PCR-RFLP Method for Genotyping of Common IL28B Polymorphisms: A Useful Pharmacogenetic Tool for Prediction of Hepatitis C Treatment Response
|OA=1
}}

{{PMID Auto
|PMID=22156487
|Title=Association of interleukin-28B and hepatitis C genotype 1 with a high viral load and response to pegylated interferon plus ribavirin therapy
}}

{{PMID Auto
|PMID=22193282
|Title=Host interleukin-28B genetic variants versus viral kinetics in determining responses to standard-of-care for Asians with hepatitis C genotype 1.
}}

{{PMID Auto
|PMID=22649509
|Title=IL28B Genetic Variation Is Associated with Spontaneous Clearance of Hepatitis C Virus, Treatment Response, Serum IL-28B Levels in Chinese Population
|OA=1
}}

{{PMID Auto
|PMID=22591106
|Title=Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.
}}

{{PMID Auto
|PMID=22387386
|Title=Predicting sustained viral response to hepatitis C using a rapid and simple IL28B rs8099917 genotyping assay.
}}

{{PMID Auto
|PMID=22713131
|Title=Prediction of response to pegylated-interferon-Â¿ and ribavirin therapy in Chinese patients infected with different hepatitis C virus genotype
|OA=1
}}

{{PMID Auto
|PMID=20434452
|Title=Hepatic ISG expression is associated with genetic variation in interleukin 28B and the outcome of IFN therapy for chronic hepatitis C.
}}

{{PMID Auto
|PMID=20648473
|Title=Amino acid substitution in hepatitis C virus core region and genetic variation near the interleukin 28B gene predict viral response to telaprevir with peginterferon and ribavirin.
}}

{{PMID Auto
|PMID=20708617
|Title=Variants in IL28B in liver recipients and donors correlate with response to peg-interferon and ribavirin therapy for recurrent hepatitis C.
}}

{{PMID Auto
|PMID=20728570
|Title=Impact of IL28B genotype on the early and sustained virologic response in treatment-naive patients with chronic hepatitis C.
}}

{{PMID Auto
|PMID=21048934
|Title=IL28B SNP rs8099917 is strongly associated with pegylated interferon-alpha and ribavirin therapy treatment failure in HCV/HIV-1 coinfected patients.
|OA=1
}}

{{PMID Auto
|PMID=21080244
|Title=The IL-28 genotype: how it will affect the care of patients with hepatitis C virus infection.
}}

{{PMID Auto
|PMID=21112657
|Title=Importance of IL28B gene polymorphisms in hepatitis C virus genotype 2 and 3 infected patients.
}}

{{PMID Auto
|PMID=21112660
|Title=Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b.
}}

{{PMID Auto
|PMID=21145800
|Title=IL28 variation affects expression of interferon stimulated genes and peg-interferon and ribavirin therapy.
}}

{{PMID Auto
|PMID=21145807
|Title=Early virologic response and IL28B polymorphisms in patients with chronic hepatitis C genotype 3 treated with peginterferon alfa-2a and ribavirin.
}}

{{PMID Auto
|PMID=21254157
|Title=Role of interleukin-28B polymorphisms in the treatment of hepatitis C virus genotype 2 infection in Asian patients.
}}

{{PMID Auto
|PMID=21274371
|Title=Peginterferon and ribavirin treatment for hepatitis C virus infection.
|OA=1
}}

{{PMID Auto
|PMID=21321200
|Title=Association of IL28B gene variations with mathematical modeling of viral kinetics in chronic hepatitis C patients with IFN plus ribavirin therapy.
|OA=1
}}

{{PMID Auto
|PMID=21325786
|Title=Amino Acid Substitution in HCV Core Region and Genetic Variation near the IL28B Gene Affect Viral Dynamics during Telaprevir, Peginterferon and Ribavirin Treatment.
}}

{{PMID Auto
|PMID=21354446
|Title=IL28B polymorphisms predict reduction of HCV RNA from the first day of therapy in chronic hepatitis C.
}}

{{PMID Auto
|PMID=21360545
|Title=Association of IL28B variants with response to pegylated-interferon alpha plus ribavirin combination therapy reveals intersubgenotypic differences between genotypes 2a and 2b.
}}

{{PMID Auto
|PMID=21374656
|Title=IL28B genetic variation and treatment response in patients with hepatitis C virus genotype 3 infection.
}}

{{PMID Auto
|PMID=21389156
|Title=The rs8099917 polymorphism, when determined by a suitable genotyping method, is a better predictor for response to pegylated alpha interferon/ribavirin therapy in Japanese patients than other single nucleotide polymorphisms associated with interleukin-28B.
|OA=1
}}

{{PMID Auto
|PMID=21466653
|Title=Donor and recipient IL28B polymorphisms in HCV-infected patients undergoing antiviral therapy before and after liver transplantation.
}}

{{PMID Auto
|PMID=21501223
|Title=Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in Asian patients.
}}

{{PMID Auto
|PMID=21503910
|Title=Prediction of response to peginterferon-alfa-2b plus ribavirin therapy in Japanese patients infected with hepatitis C virus genotype 1b.
}}

{{PMID Auto
|PMID=21567424
|Title=Impact of genetic polymorphisms near the IL28B gene and amino acid substitutions in the hepatitis C virus core region on interferon sensitivity/resistance in patients with chronic hepatitis C.
}}

{{PMID Auto
|PMID=21613433
|Title=Interleukin-28B genotyping by melt-mismatch amplification mutation assay PCR analysis using single nucleotide polymorphisms rs12979860 and rs8099917, a useful tool for prediction of therapy response in hepatitis C patients.
|OA=1
}}

{{PMID Auto
|PMID=21692944
|Title=IL28B polymorphisms determine early viral kinetics and treatment outcome in patients receiving peginterferon/ribavirin for chronic hepatitis C genotype 1.
}}

{{PMID Auto
|PMID=21703176
|Title=Interleukin-28B genetic variants in identification of hepatitis C virus genotype 1 patients responding to 24 weeks peginterferon/ribavirin.
}}

{{PMID Auto
|PMID=21704279
|Title=Simultaneous genotyping of rs12979860 and rs8099917 variants near the IL28B locus associated with HCV clearance and treatment response.
|OA=1
}}

{{PMID Auto
|PMID=21721028
|Title=Genetic variation in the interleukin-28B gene is not associated with fibrosis progression in patients with chronic hepatitis C and known date of infection.
}}

{{PMID Auto
|PMID=21739446
|Title=Antiviral combination therapy with peginterferon and ribavirin does not induce a therapeutically resistant mutation in the HCV core region regardless of genetic polymorphism near the IL28B gene.
}}

{{PMID Auto
|PMID=21879313
|Title=Genotype rs8099917 near the IL28B gene and amino acid substitution at position 70 in the core region of the hepatitis C virus are determinants of serum apolipoprotein B-100 concentration in chronic hepatitis C.
}}

{{PMID Auto
|PMID=21889215
|Title=IL28B polymorphisms are not associated with the response to interferon-beta in multiple sclerosis.
}}

{{PMID Auto
|PMID=21898478
|Title=Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response.
}}

{{PMID Auto
|PMID=21900787
|Title=A single IL28B genotype SNP rs12979860 determination predicts treatment response in patients with chronic hepatitis C Genotype 1 virus.
}}

{{PMID Auto
|PMID=21907615
|Title=Polymorphism near the IL28B gene in Korean hepatitis C virus-infected patients treated with peg-interferon plus ribavirin.
}}

{{PMID Auto
|PMID=21911885
|Title=Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.
}}

{{PMID Auto
|PMID=22013224
|Title=IL28B rs12979860 genotype and spontaneous clearance of hepatitis C virus in a multi-ethnic cohort of injection drug users: evidence for a supra-additive association.
|OA=1
}}

{{PMID Auto
|PMID=22095536
|Title=Predictive value of early viral dynamics during peginterferon and ribavirin combination therapy based on genetic polymorphisms near the IL28B gene in patients infected with HCV genotype 1b.
}}

{{PMID Auto
|PMID=22098416
|Title=IL28B polymorphisms are markers of therapy response and are influenced by genetic ancestry in chronic hepatitis C patients from an admixed population.
}}

{{PMID Auto
|PMID=22098610
|Title=Clinical impact of HFE mutations in Japanese patients with chronic hepatitis C.
}}

{{PMID Auto
|PMID=22180014
|Title=IL28B alleles associated with poor hepatitis C virus (HCV) clearance protect against inflammation and fibrosis in patients infected with non-1 HCV genotypes.
}}

{{PMID Auto
|PMID=22180419
|Title=IL28B polymorphisms influence stage of fibrosis and spontaneous or interferon-induced viral clearance in thalassemia patients with hepatitis C virus infection.
|OA=1
}}

{{PMID Auto
|PMID=22192885
|Title=Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection.
}}

{{PMID Auto
|PMID=22209781
|Title=Evaluation of susceptibility locus for response to interferon-alpha based therapy in chronic hepatitis B patients in Chinese.
}}

{{PMID Auto
|PMID=22239510
|Title=Serum PAI-1 is a novel predictor for response to pegylated interferon-alpha-2b plus ribavirin therapy in chronic hepatitis C virus infection.
}}

{{PMID Auto
|PMID=22245236
|Title=Association of IL28B gene polymorphism with development of hepatocellular carcinoma in Japanese patients with chronic hepatitis C virus infection.
}}

{{PMID Auto
|PMID=22310928
|Title=Genetic variation in IL28B is associated with the development of hepatitis B-related hepatocellular carcinoma.
}}

{{PMID Auto
|PMID=22314430
|Title=IL28B and PNPLA3 polymorphisms affect histological liver damage in patients with non-alcoholic fatty liver disease.
}}

{{PMID Auto
|PMID=22325058
|Title=Association of polymorphisms in interleukin-18 and interleukin-28B with Hepatitis B recurrence after liver transplantation in Chinese Han population.
}}

{{PMID Auto
|PMID=22329371
|Title=IL28B genetic variants and gender are associated with spontaneous clearance of hepatitis C virus infection.
}}

{{PMID Auto
|PMID=22350701
|Title=IL28B polymorphism is associated with fatty change in the liver of chronic hepatitis C patients.
}}

{{PMID Auto
|PMID=22382633
|Title=Randomized trial of peginterferon alpha-2a plus ribavirin versus peginterferon alpha-2b plus ribavirin for chronic hepatitis C in Japanese patients.
}}

{{PMID Auto
|PMID=22404723
|Title=Lymphotropic hepatitis C virus has an interferon-resistant phenotype.
}}

{{PMID Auto
|PMID=22432893
|Title=IL28B SNP of donors and recipients can predict virological response to PEGIFN/RBV therapy in patients with recurrent hepatitis C after living donor liver transplantation.
}}

{{PMID Auto
|PMID=22438096
|Title=Association of two polymorphisms of the IL28B gene with viral factors and treatment response in 1,518 patients infected with hepatitis C virus.
}}

{{PMID Auto
|PMID=22441534
|Title=Prediction of response to pegylated interferon/ribavirin combination therapy for chronic hepatitis C genotype 1b and high viral load.
}}

{{PMID Auto
|PMID=22505587
|Title=Vitamin D levels and IL28B polymorphisms are related to rapid virological response to standard of care in genotype 1 chronic hepatitis C.
}}

{{PMID Auto
|PMID=22537149
|Title=Development of new IL28B genotyping method using Invader Plus assay.
}}

{{PMID Auto
|PMID=22613000
|Title=Insulin resistance undermines the advantages of IL28B polymorphism in the pegylated interferon alpha-2b and ribavirin treatment of chronic hepatitis C patients with genotype 1.
}}

{{PMID Auto
|PMID=22664181
|Title=A straightforward genotyping of the relevant IL28B SNPs for the prediction of hepatitis C treatment outcome.
}}

{{PMID Auto
|PMID=22966241
|Title=The impact of interferon lambda 3 gene polymorphism on natural course and treatment of hepatitis C
|OA=1
}}

{{GET Evidence
|impact=pathogenic
|qualified_impact=Insufficiently evaluated pathogenic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs8099917
|overall_frequency_n=20
|overall_frequency_d=128
|overall_frequency=0.15625
|n_genomes=12
|n_genomes_annotated=0
|n_haplomes=16
|n_articles=1
|n_articles_annotated=0
|in_gwas=Y
|in_pharmgkb=Y
|autoscore=2
|webscore=N
}}

{{PMID Auto
|PMID=23118765
|Title=Hepatitis C virus clearance after discontinuation of pegylated interferon alpha-2a monotherapy in a child
|OA=1
}}

{{PMID Auto
|PMID=23133602
|Title=Pharmacogenetics of Efficacy and Safety of HCV Treatment in HCV-HIV Coinfected Patients: Significant Associations with IL28B and SOCS3 Gene Variants
|OA=1
}}

{{PMID Auto
|PMID=23149444
|Title=Negative Predictive Value of IL28B, SLC28A2, and CYP27B1 SNPs and Low RBV Plasma Exposure for Therapeutic Response to PEG/IFN-RBV Treatment
}}

{{PMID Auto
|PMID=23189850
|Title=[Genetic variation of IL-28B is associated with treatment response of patients with chronic hepatitis C]
}}

{{PMID Auto
|PMID=23252241
|Title=[Immunogenetic predictors of a rapid virologic response to antiviral therapy in patients with chronic hepatitis C]
}}

{{PMID Auto
|PMID=23442843
|Title=Role of Interleukin 28B-related Gene Polymorphisms in Chronic Hepatitis C and the Response to Antiviral Therapy in Koreans
}}

{{PMID Auto
|PMID=23490371
|Title=Genetic variations in host IL28B links to the detection of peripheral blood mononuclear cells-associated hepatitis C virus RNA in chronically infected patients
}}

{{PMID Auto
|PMID=23029188
|Title=Test of IL28B polymorphisms in chronic hepatitis C patients treated with PegIFN and ribavirin depends on HCV genotypes: results from a meta-analysis
|OA=1
}}

{{PMID Auto
|PMID=23109451
|Title=IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population
}}

{{PMID Auto
|PMID=23020144
|Title=Polymorphisms in interleukin-10 and interleukin-28B genes in Egyptian patients with chronic hepatitis C virus genotype 4 and their effect on the response to pegylated interferon/ribavirin-therapy
}}

{{PMID Auto
|PMID=23782163
|Title=Interleukin-28B genetic variations and spontaneous clearance of hepatitis C antibody-positive blood donors in China
}}

{{PMID Auto
|PMID=23860735
|Title=Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C
}}

{{PMID Auto
|PMID=23866096
|Title=The predictive value of IL28B rs12979860, rs11881222 and rs8099917 polymorphisms and IP-10 in the therapeutic response of Egyptian genotype 4 patients
}}

{{PMID Auto
|PMID=23231085
|Title=IL28B polymorphisms predict response to therapy among chronic hepatitis C patients with HCV genotype 4
}}

{{PMID Auto
|PMID=23426277
|Title=Association of interleukin-28B genotype and hepatocellular carcinoma recurrence in patients with chronic hepatitis C
}}

{{PMID Auto
|PMID=24130799
|Title=microRNA-122 Abundance in Hepatocellular Carcinoma and Non-Tumor Liver Tissue from Japanese Patients with Persistent HCV versus HBV Infection
|OA=1
}}

{{PMID Auto
|PMID=24192751
|Title=Telaprevir is effective given every 12 hours at 750 mg with peginterferon-alfa-2b and ribavirin to Japanese patients with HCV-1b IL28B rs8099917 TT
}}

{{PMID Auto
|PMID=24197875
|Title=Utility of Telaprevir-Resistant Variant Detection for Prediction of Treatment Efficacy in HCV Genotype 1
}}

{{PMID Auto
|PMID=23197895
|Title=Novel biosensor-based microarray assay for detecting rs8099917 and rs12979860 genotypes
|OA=1
}}

{{PMID Auto
|PMID=24303092
|Title=IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase
|OA=1
}}

{{PMID Auto
|PMID=24355007
|Title=Genetic polymorphism in IFNL4 and response to pegylated interferon-α and ribavirin in Japanese chronic hepatitis C patients
}}

{{PMID Auto
|PMID=24477330
|Title=A case of successful hepatitis C virus eradication by 24 weeks of telaprevir-based triple therapy for a hemophilia patient with hepatitis C virus/human immunodeficiency virus co-infection who previously failed pegylated interferon-α and ribavirin therapy
}}

{{PMID Auto
|PMID=24553484
|Title=Impact of Comorbid Hepatic Steatosis on Treatment of Chronic Hepatitis C in Japanese Patients and the Relationship with Genetic Polymorphism of IL28B, PNPLA3 and LDL Receptor
}}

{{PMID Auto
|PMID=24620020
|Title=Immunomodulatory function of interleukin-28B during primary infection with Cytomegalovirus
}}

{{PMID Auto
|PMID=24621321
|Title=Severe thrombocytopenia in a patient with inosine triphosphatase (ITPA)-CC genotype caused by pegylated interferon (IFN)-alpha-2a with ribavirin therapy: a case report
|OA=1
}}

{{PMID Auto
|PMID=22536875
|Title=Factors responsible for the discrepancy between IL28B polymorphism prediction and the viral response to peginterferon plus ribavirin therapy in Japanese chronic hepatitis C patients.
}}

{{PMID Auto
|PMID=22612669
|Title=Efficacy of reduction therapy of natural human beta-interferon and ribavirin in elderly patients with chronic hepatitis C, genotype 1b and high viral load.
}}

{{PMID Auto
|PMID=22626609
|Title=Factors that predict response of patients with hepatitis C virus infection to boceprevir.
}}

{{PMID Auto
|PMID=22742526
|Title=Meta-analysis: the impact of IL28B polymorphisms on rapid and sustained virological response in HCV-2 and -3 patients.
}}

{{PMID Auto
|PMID=22806754
|Title=Complicated relationships of amino acid substitution in hepatitis C virus core region and IL28B genotype influencing hepatocarcinogenesis.
}}

{{PMID Auto
|PMID=22814458
|Title=Targeting both rs12979860 and rs8099917 polymorphisms with a single-tube high-resolution melting assay for IL28b genotyping.
|OA=1
}}

{{PMID Auto
|PMID=22842190
|Title=Interleukin-28B polymorphisms on the SVR in the treatment of naive chronic hepatitis C with pegylated interferon-alpha plus ribavirin: a meta-analysis.
}}

{{PMID Auto
|PMID=22850127
|Title=The genotype frequencies of IL28B polymorphisms (rs12979860, rs8099917) among Turkish patients with hepatitis C.
}}

{{PMID Auto
|PMID=22863264
|Title=Genetic polymorphism in cyclooxygenase-2 promoter affects hepatic inflammation and fibrosis in patients with chronic hepatitis C.
}}

{{PMID Auto
|PMID=22863269
|Title=Interleukin-28B (IL-28B) single-nucleotide polymorphisms and interferon plus ribavirin treatment outcome in Italian chronically HCV-infected patients.
}}

{{PMID Auto
|PMID=22889955
|Title=Raloxifene hydrochloride is an adjuvant antiviral treatment of postmenopausal women with chronic hepatitis C: a randomized trial.
}}

{{PMID Auto
|PMID=22898703
|Title=Interleukin 28B genetic polymorphisms play a minor role in identifying optimal treatment duration in HCV genotype 1 slow responders to pegylated interferon plus ribavirin.
}}

{{PMID Auto
|PMID=22913807
|Title=Genetic polymorphism of IL28B in hepatitis C-infected haemophilia patients in Israel.
}}

{{PMID Auto
|PMID=22930507
|Title=Association of IL28B genotype and viral response of hepatitis C virus genotype 2 to interferon plus ribavirin combination therapy.
}}

{{PMID Auto
|PMID=23103287
|Title=IL28B polymorphisms are associated with severity of liver disease in human immunodeficiency virus (HIV) patients coinfected with hepatitis C virus.
}}

{{PMID Auto
|PMID=23135173
|Title=Analysis of IL28B alleles with virologic response patterns and plasma cytokine levels in HIV/HCV-coinfected patients.
}}

{{PMID Auto
|PMID=23142377
|Title=Association study of IL28B: rs12979860 and rs8099917 polymorphisms with SVR in patients infected with chronic HCV genotype 1 to PEG-INF/RBV therapy using systematic meta-analysis.
}}

{{PMID Auto
|PMID=23145987
|Title=Early extensive viremia, but not rs8099917 genotype, is the only predictor for cholestatic hepatitis C after living-donor liver transplantation.
}}

{{PMID Auto
|PMID=23154876
|Title=Baseline factors and early viral response (week 4) to antiviral therapy with peginterferon and ribavirin for predicting sustained virologic response in patients infected with hepatitis C virus genotype 1: a multicenter study.
}}

{{PMID Auto
|PMID=23161429
|Title=Add-on therapy of pitavastatin and eicosapentaenoic acid improves outcome of peginterferon plus ribavirin treatment for chronic hepatitis C.
}}

{{PMID Auto
|PMID=23213063
|Title=Human blood dendritic cell antigen 3 (BDCA3)(+) dendritic cells are a potent producer of interferon-lambda in response to hepatitis C virus.
}}

{{PMID Auto
|PMID=23216931
|Title=Serum peptides, represented by complement 3f des-arginine, are useful for prediction of the response to pegylated interferon-alpha plus ribavirin in patients with chronic hepatitis C.
}}

{{PMID Auto
|PMID=23246359
|Title=Profound week 4 interferon responsiveness is mandatory for hepatitis C genotype 1 patients with unfavorable IL-28B genotype.
}}

{{PMID Auto
|PMID=23266640
|Title=Interleukin-28B rs12979860C/T and rs8099917T/G contribute to spontaneous clearance of hepatitis C virus in Caucasians.
}}

{{PMID Auto
|PMID=23296193
|Title=IL-21R gene polymorphisms and serum IL-21 levels predict virological response to interferon-based therapy in Asian chronic hepatitis C patients.
}}

{{PMID Auto
|PMID=23297176
|Title=Model incorporating the ITPA genotype identifies patients at high risk of anemia and treatment failure with pegylated-interferon plus ribavirin therapy for chronic hepatitis C.
}}

{{PMID Auto
|PMID=23314745
|Title=Impact of IL-28B polymorphisms on pegylated interferon plus ribavirin treatment response in children and adolescents infected with HCV genotypes 1 and 4.
|OA=1
}}

{{PMID Auto
|PMID=23333445
|Title=Differential effects of donor and recipient IL28B and DDX58 SNPs on severity of HCV after liver transplantation.
|OA=1
}}

{{PMID Auto
|PMID=23356752
|Title=Pegylated interferon monotherapy in patients with chronic hepatitis C with low viremia and its relationship to mutations in the NS5A region and the single nucleotide polymorphism of interleukin-28B.
}}

{{PMID Auto
|PMID=23449268
|Title=HLA-DP and IL28B polymorphisms: influence of host genome on hepatitis B surface antigen seroclearance in chronic hepatitis B.
}}

{{PMID Auto
|PMID=23455512
|Title=IL28B SNP screening and distribution in the French Canadian population using a rapid PCR-based test.
|OA=1
}}

{{PMID Auto
|PMID=23486666
|Title='Favourable' IL28B polymorphisms are associated with a marked increase in baseline viral load in hepatitis C virus subtype 3a infection and do not predict a sustained virological response after 24 weeks of therapy.
}}

{{PMID Auto
|PMID=23490377
|Title=Value of IL28B genotyping in patients with HCV-related mixed cryoglobulinemia: results of a large, prospective study.
}}

{{PMID Auto
|PMID=23490380
|Title=An automated rapid detection system using the quenching probe method for detecting interleukin 28B and inosine triphosphatase single nucleotide polymorphisms in chronic hepatitis C.
}}

{{PMID Auto
|PMID=23560893
|Title=Clinical utility of host genetic IL-28B variants in hepatitis C virus genotype 1 Asian patients retreated with pegylated interferon plus ribavirin.
}}

{{PMID Auto
|PMID=23565619
|Title=IL28RA polymorphism is associated with early hepatitis C virus (HCV) treatment failure in human immunodeficiency virus-/HCV-coinfected patients.
}}

{{PMID Auto
|PMID=23586360
|Title=Association between gene polymorphisms of IL-28 and response to lamivudine in Chinese rural patients with chronic hepatitis B.
}}

{{PMID Auto
|PMID=23591768
|Title=Ex vivo induction of IFN-lambda3 by a TLR7 agonist determines response to Peg-IFN/ribavirin therapy in chronic hepatitis C patients.
|OA=1
}}

{{PMID Auto
|PMID=23611115
|Title=Impact of interleukin 28B polymorphisms on spontaneous clearance of hepatitis C virus infection: a meta-analysis.
}}

{{PMID Auto
|PMID=23611467
|Title=CARD8 gene encoding a protein of innate immunity is expressed in human atherosclerosis and associated with markers of inflammation.
}}

{{PMID Auto
|PMID=23613588
|Title=Serum microRNA-122 level correlates with virologic responses to pegylated interferon therapy in chronic hepatitis C.
|OA=1
}}

{{PMID Auto
|PMID=23689988
|Title=Using early viral kinetics to predict antiviral outcome in response-guided pegylated interferon plus ribavirin therapy among patients with hepatitis C virus genotype 1.
}}

{{PMID Auto
|PMID=23689989
|Title=IL28B minor allele is associated with a younger age of onset of hepatocellular carcinoma in patients with chronic hepatitis C virus infection.
}}

{{PMID Auto
|PMID=23730840
|Title=Role of IL28B and inosine triphosphatase polymorphisms in the treatment of chronic hepatitis C virus genotype 6 infection.
}}

{{PMID Auto
|PMID=23777929
|Title=Searching for an immunogenetic factor that will illuminate susceptibility to non-tuberculous mycobacterial disease.
}}

{{PMID Auto
|PMID=23829453
|Title=Value of interleukin-28B genetic polymorphism on retreatment outcomes of chronic hepatitis C genotype 1 relapsers by peginterferon alfa plus ribavirin.
}}

{{PMID Auto
|PMID=24750345
|Title=ITPA genetic variants influence efficacy of PEG-IFN/RBV therapy in older patients infected with HCV genotype 1 and favourable IL28B type
}}

{{PMID Auto
|PMID=24379268
|Title=[The role of hepcidin and polymorphisms in the regulatory region of the IL-28B gene in HCV infections]
}}

{{PMID Auto
|PMID=24914551
|Title=Impact of Host IL28B rs12979860, rs8099917 in Interferon Responsiveness and Advanced Liver Disease in Chronic Genotype 3 Hepatitis C Patients
}}

{{PMID Auto
|PMID=24929144
|Title=KIR3DL1-HLA-Bw4 Combination and IL28B Polymorphism Predict Response to Peg-IFN and Ribavirin with and without Telaprevir in Chronic Hepatitis C
}}

{{PMID Auto
|PMID=24379617
|Title=Interleukin 28B polymorphisms as predictor of response in hepatitis C virus genotype 2 and 3 infected patients
}}

{{PMID Auto
|PMID=25032184
|Title=No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients
}}

{{PMID Auto
|PMID=24204859
|Title=Association of IFNL3 rs12979860 and rs8099917 with biochemical predictors of interferon responsiveness in chronic hepatitis C virus infection
}}

{{PMID Auto
|PMID=24117654
|Title=Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b
}}

{{PMID Auto
|PMID=25233462
|Title=IL28B Gene Polymorphism SNP rs8099917 Genotype GG Is Associated with HTLV-1-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) in HTLV-1 Carriers
}}

{{PMID Auto
|PMID=24349054
|Title=No correlation between PNPLA3 rs738409 genotype and fatty liver and hepatic cirrhosis in Japanese patients with HCV
}}
{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Affy GenomeWide 6}}
{{on chip | HumanOmni1Quad}}
{{on chip | Illumina Human 1M}}